Madrigal Pharmaceuticals, Inc.
MDGL
$579.89
$6.741.18%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 34.99% | 55.05% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 34.99% | 55.05% | |||
| Cost of Revenue | 99.91% | 100.86% | |||
| Gross Profit | 32.10% | 53.49% | |||
| SG&A Expenses | 6.23% | 17.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 54.32% | 20.06% | |||
| Operating Income | -141.46% | 40.48% | |||
| Income Before Tax | -170.07% | 42.27% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -170.07% | 42.27% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -170.07% | 42.27% | |||
| EBIT | -141.46% | 40.48% | |||
| EBITDA | -142.64% | 40.68% | |||
| EPS Basic | -166.77% | 42.57% | |||
| Normalized Basic EPS | -160.27% | 42.57% | |||
| EPS Diluted | -166.77% | 42.57% | |||
| Normalized Diluted EPS | -160.27% | 42.57% | |||
| Average Basic Shares Outstanding | 1.24% | 0.52% | |||
| Average Diluted Shares Outstanding | 1.24% | 0.52% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||